82 results on '"Osman, Iman"'
Search Results
2. The association between mediators of the receptor for advanced glycation end product (RAGE) axis and immune checkpoint inhibitor (ICI)–induced colitis in patients with melanoma.
3. Association of pre-existing autoimmune diseases in melanoma patients receiving immune checkpoint inhibition with improved survival and increased toxicity.
4. The risk and tropism of central nervous system metastases (CNS) in patients with stage II cutaneous melanoma.
5. Outcomes for hospitalized cancer patients with COVID-19 during the height of pandemic in New York City.
6. Genome-wide association study to reveal novel germline markers of melanoma survival.
7. Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma.
8. Association of pathogenic germline variant KDR Q472H with angiogenesis and resistance to treatment in melanoma.
9. Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment.
10. Effect of administration of systemic steroids on survival benefit associated with immunotherapy-induced skin toxicity.
11. Using digital-image analysis of tumor-infiltrating lymphocytes to predict survival outcomes in primary melanoma.
12. CDC20 is a novel potential therapeutic target in NF1-mutant melanoma.
13. Using machine learning to predict immunotherapy response in advanced melanoma.
14. Using autoantibody signatures to predict immunotherapy discontinuation in melanoma patients.
15. Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
16. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent
17. The relationship between obesity and immunotherapy: It's complicated.
18. Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.
19. The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th edition.
20. Mutation burden in conjunction with MAPK-pathway mutation status as a prognostic biomarker of overall melanoma survival.
21. Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.
22. Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.
23. Gut microbiome and immunotherapy response in melanoma patients.
24. Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.
25. Using deep learning algorithms on histopathology images for the prediction of BRAF and NRAS mutations in invasive melanoma.
26. Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.
27. Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.
28. Novel germline risk loci in familial melanoma (FM).
29. Targeting EZH2 in acral lentiginous melanoma (ALM).
30. Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.
31. Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.
32. Mutation burden as a potential prognostic marker of melanoma progression and survival.
33. A threshold of clinically significant reduced PTEN expression in melanoma.
34. Metastatic melanoma outcomes in the era of commercially available targeted therapy and immunotherapy.
35. Analysis of TERT promoter mutations, polymorphisms, clinicopathologic features and recurrence-free survival in primary melanoma.
36. The identification of novel genetic risk loci in uveal melanoma.
37. Prognostic value of mitoses in thick primary melanoma.
38. Impact of aging on immune response and survival in melanoma.
39. Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.
40. Targeted next-generation sequencing of melanoma patient samples to reveal mutations in non-protein coding regions of targetable oncogenes.
41. Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.
42. The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.
43. Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.
44. The expression quantitative trait loci (eQTLs) and their association with melanoma clinical outcomes.
45. The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.
46. The impact of primary melanoma histotype on overall survival and response to immunotherapy.
47. Impact of socioeconomic status (SES) and ethnicity on melanoma presentation and recurrence in Caucasian patients.
48. Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.
49. De novo versus nevus-associated melanomas: Differences in associations with prognostic indicators and survival.
50. Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.